Please login to the form below

Not currently logged in
Email:
Password:

West reveals 1m share repurchase programme

US-based West Pharmaceutical Services, a manufacturer of closure systems and syringe components for use with injectable drugs, has said that its board has approved a share repurchase programme of up to one million shares of its common stock.

US-based West Pharmaceutical Services, a manufacturer of closure systems and syringe components for use with injectable drugs, has said that its board has approved a share repurchase programme of up to one million shares of its common stock.

The programme will go into effect immediately and allow the company to repurchase its shares on the open market or in privately negotiated transactions in accordance with the Securities and Exchange Commission. The programme should complete within one year.

Donald E Morel Jr, West's chairman and CEO , said: "The current valuation of West stock makes repurchases a solid investment and represents an attractive opportunity to enhance long-term shareholder value."

"The board's action reflects our great confidence in our long-term business plan, the strength of our balance sheet and strong operating cash flow. From a financial perspective, we are well-positioned to fund our expansion activities, invest in growth opportunities through our Innovation Programmes, pay a dividend and buy back shares, which taken together, will create value for our shareholders," added Morel.

10th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

ema1
The European Medicines Agency: PRIME’d for access?
Leela Barham examines the impact of the EMA's PRIME fast track system after two years...
How can pharma engage with key stakeholders on NHS service transformation?
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare consulting team, explain how pharma should make its case for change...
michael elliot
The race for an HIV ‘cure’
Supercharging therapies as pharma and patients work together...

Infographics